Table 3.
Factors associated with non‐sustained virologic response in patients with hepatitis C virus (HCV) genotype 1 after completing antiviral therapy with elbasvir/grazoprevir
| Factor | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Odds ratio (95% CI) | P‐value | Odds ratio (95% CI) | P‐value | |
| Age | 1.069 (0.999–1.162) | 0.0538 | — | — |
| Sex, male | 1.819 (0.511–7.222) | 0.3547 | — | — |
| History of IFN therapy, yes | 6.619 (1.837–26.54) | 0.0044 | 4.25 (0.308–104.5) | 0.2706 |
| History of DAA therapy, yes | 162.0 (34.49–1199.2) | <0.0001 | 5.293 (0.161–94.86) | 0.3070 |
| History of HCC, yes | 3.895 (0.811–14.73) | 0.0840 | — | — |
| Cirrhosis, yes | 0.384 (0.021–2.090) | 0.3085 | — | — |
| NS5A‐L31, mutant† | 0.000 (0.000–9.593) | 0.4845 | — | — |
| NS5A‐Y93, mutant‡ | 0.000 (0.000–0.000) | 0.1041 | — | — |
| NS5A‐L31/‐Y93 double mutation, yes | 1278 (153.9–31 220) | <0.0001 | 356.3 (23.91–16 940) | <.0001 |
| Platelet count | 0.954 (0.848–1.048) | 0.3689 | — | — |
| AST | 1.001 (0.978–1.011) | 0.9226 | — | — |
| ALT | 1.001 (0.981–1.011) | 0.8975 | — | — |
| eGFR | 1.013 (0.988–1.043) | 0.3371 | — | — |
| M2BPGi | 0.983 (0.687–1.246) | 0.9054 | — | — |
| FIB‐4 index | 1.047 (0.817–1.257) | 0.6777 | — | — |
| α‐Fetoprotein | 1.001 (0.957–1.015) | 0.9029 | — | — |
| HCV‐RNA | 1.691 (0.735–5.011) | 0.2460 | — | — |
†
Mutation of L31 alone (double mutation with Y93 is excluded).
‡
Mutation of Y93 alone (double mutation with L31 is excluded).
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DAA, direct‐acting antiviral; eGFR, estimated glomerular filtration rate; FIB‐4, Fibrosis‐4; HCC, hepatocellular carcinoma; IFN, interferon; M2BPGi, Mac‐2 binding protein glycosylation isomer; NS5A, non‐structural protein 5A; —, not included